Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255125 · ClinicalTrials.gov registry record · Phase 3
Role of Soy Supplementation in Prostate Cancer Development
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT00255125: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT00255125 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00255125, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. Patient's blood and prostate tissue will be evaluated to determine the effects of the soy supplement on the prostate tissue.
Interventions
- DRUG Placebo
- DRUG Soy Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255125
The ClinicalTrials.gov registry entry for NCT00255125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00255125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255125 about?
NCT00255125 is a clinical study titled "Role of Soy Supplementation in Prostate Cancer Development". This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of the...
What is the current status of trial NCT00255125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2005-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00255125?
The interventions under investigation include: Placebo (DRUG), Soy Supplement (DRUG).
Who is sponsoring clinical trial NCT00255125?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.